Radiation plus nimotuzumab for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial compares radiation therapy alone versus radiation therapy plus a targeted drug called nimotuzumab for people with advanced head and neck cancer who cannot take cisplatin chemotherapy. The goal is to see if adding nimotuzumab improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage III or IV head and neck cancer (in the mouth, throat, or voice box) that cannot be removed by surgery.
- You cannot take cisplatin (a standard chemotherapy drug) because of your age, kidney problems, hearing loss, nerve damage, or other medical reasons.
- You are generally healthy enough to receive radiation therapy (ECOG performance status 0 or 1).
- You have not had certain other cancer treatments or vaccines in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
This study tests whether adding two different drugs (nimotuzumab and benmelstobart) to standard radiation therapy after surgery can help improve outcomes for people with intermediate-risk head and neck cancer. It looks at whether the combination slows cancer growth or reduces the chances of it coming back.
This trial tests a combination of two drugs (nimotuzumab and adebrelimab) along with chemotherapy for people with head and neck cancer that has returned or spread, and who cannot take the standard chemo drug cisplatin. The goal is to see if this combination works and is safe for these patients.
This trial tests a targeted drug (nimotuzumab) combined with radiation therapy for older adults with cervical cancer. The goal is to improve treatment outcomes for those who cannot tolerate chemotherapy.
Hear when a new Head & Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.